• Home
  • Product Information
  • Reconstitution
  • Clinical
    • Clinical Safety Profile
    • Adult Studies
    • Adult & Adolescent Studies
    • Pediatric Studies
  • Patient resources
nuwiq.canuwiq.ca
nuwiq.canuwiq.ca
  • Home
  • Product Information
  • Reconstitution
  • Clinical
    • Clinical Safety Profile
    • Adult Studies
    • Adult & Adolescent Studies
    • Pediatric Studies
  • Patient resources

Product Information

Reconstitution Instructions

Clinical Studies

Nuwiq® (Antihemophilic Factor, Recombinant, B-Domain deleted, simoctocog alfa)

Nuwiq® is indicated for the treatment and prophylaxis of bleeding in patients of all ages suffering with hemophilia A (congenital factor VIII deficiency).Nuwiq® is also indicated for the peri-operative treatment of hemophilia A patients.

Patient Resources

Nuwiq® patient brochure, ProCare home care infusion program, reconstitution guide, storage information and cooler bag.

Safety Information

Important safety information, warnings, precautions and how to report suspected adverse events.

Most Commented Posts

Recent Comments

  • HB-Themes on Electrik Bulb Curabitur nulla lorem, commodo eget metus bibendum, vulputate rhoncus purus.…
  • HB-Themes on Electrik Bulb Curabitur nulla lorem, commodo eget metus bibendum, vulputate rhoncus purus.…
  • HB-Themes on Electrik Bulb Nulla sit amet scelerisque elit. Cras ac hendrerit nisl. Praesent…

Responsive Ads

Advertisment

Most Liked Posts

[Twitter Widget Error] You need to authenticate your Twitter App first. Go to Highend Options > Social Links. Read the documentation to find out more.

Find us on

    Copyright © 2020 Octapharma
    Octapharma Canada Inc. | 308 - 214 King Street West | Toronto, ON | M5H 3S6

    • Legal Statement
    • Privacy Statement
    • Sitemap
    • enEnglish
    • frFrançais